Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company specializing in biomarker and AI-driven diagnostics for chronic low back pain, has appointed Daniel Keefe as Commercial Director for the Western United States. The move aims to accelerate the adoption of Nociscan, the company's cloud-based platform that noninvasively helps physicians identify painful discs in the lumbar spine.
Keefe brings over 20 years of experience in medical device and healthcare technology sales, including leadership roles at Centinel Spine, Brainlab, Zimmer Biomet, and Intuitive Surgical. Most recently, as Regional Sales Manager at Centinel Spine, he consistently exceeded performance targets and delivered significant year-over-year growth across Northern California. His expertise spans capital equipment, surgical technologies, and advanced clinical solutions in spine, orthopedics, and image-guided surgery.
"Dan brings a proven track record of driving commercial growth and expanding adoption of innovative surgical technologies. His deep experience working with spine surgeons and hospital systems, combined with his ability to build and scale high-performing territories, will be instrumental as we continue to grow our presence in the Western U.S. and support broader clinical use of Nociscan," said Brent Ness, CEO of Aclarion.
The appointment comes amid triple-digit growth in Nociscan utilization, reflecting increasing demand from academic institutions and high-volume private practice spine centers. Aclarion has established a growing presence across the Western U.S., and Keefe will lead efforts to deepen adoption in this key strategic region. "I'm excited to join Aclarion at a time when Nociscan is gaining meaningful traction across the clinical community. The ability to provide physicians with objective insight into the source of pain represents a significant advancement in how chronic low back pain is evaluated," Keefe said.
Chronic low back pain affects an estimated 266 million people worldwide. Nociscan is the first evidence-supported, cloud-based platform to help physicians distinguish between painful and nonpainful discs. It uses magnetic resonance spectroscopy data from MRI machines to quantify chemical biomarkers associated with disc pain, then applies proprietary algorithms to indicate whether a disc may be a source of pain. According to Aclarion, when all Nociscan-positive discs are treated, the surgical success rate is 97%.
The expansion of the commercial team signals Aclarion's commitment to scaling its presence in the spine diagnostics market. For more information on Nociscan, visit the company's website at www.aclarion.com or find a Nociscan center via the company's site map here.
